Comparison between ablation efficacy of 1.1 GBq and 3.7 GBq 131I for low- and intermediate-risk differentiated thyroid carcinoma
10.3760/cma.j.issn.2095-2848.2019.09.004
- VernacularTitle: 1.1 GBq和3.7 GBq 131I对中低危分化型甲状腺癌的清甲疗效比较
- Author:
Yuyan JIANG
1
;
Jian TAN
;
Guizhi ZHANG
;
Zhaowei MENG
;
Lingyun XU
;
Fuhai ZHANG
;
Renfei WANG
Author Information
1. Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
- Publication Type:Clinical Trail
- Keywords:
Thyroid neoplasms;
Radiotherapy;
Iodine radioisotopes;
Radiotherapy dosage;
Treatment outcome
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2019;39(9):526-531
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the ablation efficacy and therapy response with 1.1 GBq and 3.7 GBq 131I in postoperative patients with low- and intermediate-risk differentiated thyroid carcinoma(DTC).
Methods:A total of 190 patients (43 males, 147 females, age: (45.8±11.1)years) were enrolled from July 2016 to July 2017. Among them, 96 patients received 1.1 GBq 131I and 94 were given 3.7 GBq 131I. Diagnostic whole-body scan was performed 6 months after 131I ablation for treatment response evaluation, and the successful rate of 131I ablation was calculated. χ2 test or Fisher′s exact test was used for data analysis. The cut-off value of 99Tcm-pertechnetate uptake for predicting the successful rate of remnant thyroid ablation in 1.1 GBq group was determined by receiver operating characteristic (ROC) curve analysis.
Results:The successful ablation rates in 1.1 GBq and 3.7 GBq groups were 79.2%(76/96) and 81.9%(77/94), respectively (χ2=0.229, P>0.05). There was no significant difference in the therapy response between the two groups (χ2=1.371, P>0.05). The successful ablation rate in 3.7 GBq group was higher than that in 1.1 GBq group for patients with stage Ⅲ (5/6 vs 1/7, P=0.029). Moreover, for patients with 5 μg/Lvs 10/13, P=0.038). ROC curve analysis showed the cut-off value of 99Tcm-pertechnetate uptake for prediction of the successful ablation rate in 1.1 GBq group was 0.061 5.
Conclusion:The low- and intermediate-risk DTC patients with stage Ⅲ disease, 5 μg/L99Tcm-pertechnetate uptake of remnant thyroid should be given 3.7 GBq other than 1.1 GBq 131I to obtain a better ablation efficacy.
